Platinum anticancer drugs are arguably the most widely used anticancer agents in the world but serious problems remain with toxicity and resistance. Platinum(IV) compounds have numerous advantages in terms of stability and thereby, lower toxicity. In this project we will exploit these advantages along with others that we have discovered recently and our understanding of chemistry and biology of platinum(IV) to develop novel platinum(IV) compounds to the point where the industry partner can commercialise them.
|Effective start/end date||1/07/02 → 30/06/04|
- Australian Research Council (ARC): AUD147,500.00
- Institute of Drug Technology Ltd: AUD150,000.00